Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

Eli Lilly and Co. (NYSE:LLY) is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.

Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growth prospects.

Analyst Adjustments and Forecasts

Ahead of the earnings release, Bank of America Securities (BofA) has made minor adjustments to its earnings model for Eli Lilly.

Also Read: FDA Approves New Dosing Schedule For Eli Lilly’s Kisunla In Alzheimer’s Treatment

BofA analyst Tim Anderson specifically noted a slight, low single-digit percentage increase in second-quarter revenue and EPS forecasts, primarily ...